Treosulfan, Fludarabine Conditioning for HSCT in Children with Primary Immunodeficiency: UK Experience

• Excellent outcome in children post HSCT with treosulfan, fludarabine, for PID.• Better myeloid chimerism with PBSC. No increased acute GVHD grade III/IV or chronic GVHD.• 11 with SCID diagnosed at birth alive with up to 8.7 years follow up.• There was no veno- occlusive disease.

Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Mary A. Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh Nademi, Robert Chiesa, Reem Elfeky, Mark S. Pearce, Persis Amrolia, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, Andrew R. Genner Source Type: research